In the OMP-C8 PDX model, an APC mutated tumor, three cycles of anti-Rspo3 + nab-paclitaxel treatment dramatically reduced the cancer stem cell frequency by 40-fold, as assayed by the limiting dilution assay (LDA) (Fig. 4A). This evidence concerns the gene RSPO3 and neoplasm.